Estée Lauder Companies
EL
$75.69
-1.83%
The Estée Lauder Companies Inc. is a global leader in the prestige beauty market, operating across key segments including skin care, makeup, fragrance, and hair care through a portfolio of iconic brands such as Estée Lauder, Clinique, M.A.C, and La Mer. The company is distinguished by its dominant market position in high-end beauty, extensive global retail and travel distribution network, and a brand-centric strategy that commands significant pricing power and consumer loyalty. The current investor narrative is intensely focused on the company's ongoing turnaround efforts, as it grapples with a volatile recovery in key Asian travel retail markets, margin pressures from restructuring costs, and the challenge of reigniting growth after a period of significant earnings volatility and stock price decline.…
EL
Estée Lauder Companies
$75.69
Related headlines
Investment Opinion: Should I buy EL Today?
Rating: Hold. The core thesis is that EL is a high-risk, high-potential-reward turnaround story where severe operational challenges are balanced by a historically cheap valuation and iconic brands, making it suitable only for risk-tolerant investors willing to bet on a multi-year recovery.
The Hold rating is supported by several specific data points. First, valuation is at a compelling discount with a PS ratio of 2.04, near the bottom of its historical range. Second, Q2 FY2026 showed encouraging signs with 5.8% revenue growth and a return to positive net income ($162M). Third, the company maintains strong free cash flow generation ($1.14B TTM) and a robust gross margin of 73.9%. Finally, some analyst upgrades suggest the risk/reward is improving from deeply oversold levels.
The two biggest risks that could invalidate this thesis are: 1) A reversal of the recent positive earnings trend, with net income returning to deep negatives, and 2) An inability to manage its high debt load (D/E of 2.44) leading to credit concerns. This Hold would upgrade to a Buy if the PS ratio sustains below 2.0 alongside consecutive quarters of positive net income and debt reduction. It would downgrade to a Sell if revenue growth turns negative or if liquidity metrics deteriorate sharply. Currently, the stock is fairly valued for the significant risks it carries, trading at a deep discount to its own history but a premium to its current broken fundamentals.
Sign up to view all
EL 12-Month Price Forecast
EL is a classic binary turnaround bet. The neutral stance reflects the high probability (50%) of a muddled, range-bound base case where neither bulls nor bears get decisive confirmation. The substantial cash flow and brand value provide a floor, but the debt load and operational missteps create a low ceiling for multiple expansion in the near term. The stance would upgrade to bullish on evidence of two consecutive quarters of expanding operating margins and a clear debt reduction roadmap. It would turn bearish on a breakdown below the $56.66 support level or a return to consistent quarterly losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $98.40 and implied upside of +30.0% versus the current price.
Average Target
$98.40
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$61 - $98
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, indicating this large-cap stock may be experiencing a period of reduced institutional focus following its steep decline. The consensus sentiment appears mixed but leans cautiously constructive, as evidenced by recent institutional actions including a 'Buy' from Deutsche Bank and Citigroup (which upgraded from Neutral), alongside several 'Hold' or 'Equal Weight' ratings from firms like Wells Fargo and TD Cowen. The average target price and implied upside cannot be calculated from the provided data, which only includes EPS and revenue estimates, not price targets; the wide range of analyst actions and the low number of covering analysts signal high uncertainty and a lack of strong conviction in the near-term path. The pattern of recent ratings shows no major downgrades in the wake of poor performance, with some firms like Citigroup actually upgrading, which could be interpreted as a belief that the bad news is largely priced in, though the tight clustering of actions around February and March 2026 suggests analysts are in a 'wait-and-see' mode regarding the turnaround's success.
Bulls vs Bears: EL Investment Factors
The evidence currently tilts bearish due to the company's severe profitability crisis, high financial leverage, and persistent technical downtrend. However, the bull case is compelling based on valuation reaching an extreme historical discount and early signs of operational stabilization in the latest quarter. The single most important tension in the investment debate is whether the company's strong brand equity and cash flow can successfully navigate its debt-laden balance sheet and restore sustainable profitability before investor patience is exhausted. The resolution of this turnaround execution risk will determine the stock's direction.
Bullish
- Valuation at Extreme Historical Discount: The stock trades at a Price-to-Sales (PS) ratio of 2.04, which is near the absolute bottom of its observable historical range (from a low near 6.70 to highs above 29). This extreme compression suggests the market is pricing in severe pessimism, creating a potential deep-value opportunity if the company's turnaround succeeds.
- Strong Free Cash Flow & Liquidity: Despite profitability issues, the company generated $1.14 billion in free cash flow over the trailing twelve months and maintains a current ratio of 1.30. This robust cash generation provides crucial internal funding to service its high debt (debt-to-equity of 2.44) and execute its restructuring plan without an immediate liquidity crisis.
- Recent Revenue Growth & Margin Improvement: Q2 FY2026 revenue grew 5.8% year-over-year to $4.24 billion, a positive inflection from prior quarters. Concurrently, the gross margin improved to 76.55%, and the company returned to positive net income of $162 million, signaling potential early success in its turnaround efforts.
- Analyst Upgrades Amidst Weakness: Despite the stock's 33.9% decline over three months, analysts from Deutsche Bank and Citigroup have recently issued or upgraded to 'Buy' ratings. This contrarian stance suggests some institutional belief that the worst news is priced in and that the risk/reward profile is improving.
Bearish
- Severe Profitability & Balance Sheet Deterioration: The company reports a trailing net margin of -7.93% and a Return on Equity of -29.3%, indicating deep operational distress. This is compounded by a dangerously high debt-to-equity ratio of 2.44, which creates significant financial risk and interest expense pressure on any recovery.
- Persistent Technical Downtrend & High Volatility: The stock is down 33.9% over three months and trades 36% below its 52-week high, firmly in a downtrend. Its beta of 1.252 means it is 25% more volatile than the market, which has amplified losses, as shown by its -37.47 relative strength versus the S&P 500 over three months.
- Earnings Volatility & Negative Trailing EPS: Quarterly earnings have been wildly inconsistent, swinging from a net income of -$546 million in Q4 FY2025 to $162 million in Q2 FY2026. The trailing twelve-month EPS is negative at -$0.04, making traditional valuation impossible and reflecting a lack of earnings stability.
- Limited Analyst Conviction & Coverage: Only 6 analysts currently cover this large-cap stock, indicating reduced institutional focus and high uncertainty. The lack of a provided average price target further underscores the difficulty in establishing a consensus near-term valuation floor or catalyst.
EL Technical Analysis
The stock is in a pronounced downtrend, having declined 33.88% over the past three months and 23.83% over the past six months, culminating in a 1-year price change of +32.69% that is largely a function of a much higher starting point a year ago. Currently trading at $77.82, the stock sits just 37% above its 52-week low of $56.66 and 36% below its 52-week high of $121.64, positioning it in the lower third of its annual range, which suggests it is being priced for significant distress rather than momentum. Recent momentum shows a modest 1-month gain of 6.44%, which contrasts sharply with the severe 3-month loss, indicating a potential attempt at stabilization or a dead-cat bounce within a broader bearish context, further evidenced by a stark -37.47 relative strength versus the S&P 500 over three months. Key technical levels are clearly defined, with major support at the 52-week low of $56.66 and resistance near the 52-week high of $121.64; a sustained breakdown below support would signal a continuation of the downtrend, while reclaiming the $100 level would be a first step toward recovery. The stock's beta of 1.252 indicates it is approximately 25% more volatile than the broader market, which has amplified losses during the recent sell-off and necessitates careful risk management for investors.
Beta
1.25
1.25x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$57-$122
Price range past year
Annual Return
+27.0%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | +11.3% | +12.6% |
| 3m | -34.3% | +2.5% |
| 6m | -21.7% | +4.3% |
| 1y | +27.0% | +28.4% |
| ytd | -29.1% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Revenue growth has been inconsistent but showed a positive sign in the most recent quarter (Q2 FY2026), with revenue of $4.24 billion representing a 5.8% year-over-year increase, a notable improvement from the prior quarter's $3.48 billion. The skin care segment, representing $2.05 billion of the latest quarter's sales, remains the largest and most critical growth driver, while makeup at $1.16 billion and fragrance at $812 million contribute to the diversified portfolio. Profitability is under severe pressure, with the company reporting a trailing twelve-month net margin of -7.93% and a quarterly net income of $162 million in Q2, which, while positive, follows a deeply negative net income of -$546 million in the prior quarter (Q4 FY2025); the gross margin remains robust at 73.9% (76.55% in Q2), but operating margin is thin at 6.7%, indicating high operating expenses are compressing bottom-line results. The balance sheet carries significant financial risk, with a high debt-to-equity ratio of 2.44 and a return on equity of -29.3%, though it is supported by substantial liquidity with a current ratio of 1.30 and generated strong free cash flow of $1.14 billion over the trailing twelve months, providing some capacity to service debt and fund operations internally.
Quarterly Revenue
$4.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.76%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
Given the negative trailing net income and EPS of -$0.04, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 2.04 and an Enterprise Value-to-Sales (EV/Sales) of 2.31, which are depressed multiples reflecting the current operational challenges and market skepticism. Compared to the provided industry average data, a direct peer comparison is not available in the dataset; however, the stock's valuation must be assessed against its own history and sector norms for premium beauty, with the current PS ratio likely at a discount due to the profitability crisis. Historically, the stock's own PS ratio has fluctuated wildly, from a low near 6.70 to highs above 29 over the past several years; the current PS of 2.04 is near the absolute bottom of its observable historical range, suggesting the market is pricing in extreme pessimism and potentially a deep-value scenario if the company can execute its turnaround.
PE
-25.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -533x~438x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
184.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. The company's debt-to-equity ratio of 2.44 is dangerously high, creating a significant interest burden that pressures already negative profitability (trailing net margin of -7.93%). Earnings volatility is extreme, with quarterly net income swinging from -$546 million to +$162 million within two quarters, indicating unreliable bottom-line results. While free cash flow of $1.14 billion provides a buffer, revenue remains sensitive to the volatile recovery in key Asian travel retail markets, which accounted for a major portion of pre-pandemic growth.
Market & Competitive Risks are elevated. The stock's beta of 1.252 indicates it is 25% more volatile than the market, which has magnified its recent 33.9% three-month decline. Trading at a PS ratio of 2.04, a deep discount to its own history, the stock faces valuation compression risk if the turnaround stalls, but also sector rotation risk away from troubled consumer staples. Competitive intensity in prestige beauty is relentless, and the company's high operating expense structure (operating margin of 6.7%) leaves it vulnerable to more agile rivals.
Worst-Case Scenario involves a failure of the turnaround plan, leading to consecutive earnings misses, a credit rating downgrade that increases borrowing costs, and a loss of market share in core skincare and makeup segments. This could trigger a liquidity crisis despite current cash flow, forcing dilutive equity issuance or asset sales at distressed prices. The realistic downside could see the stock re-testing its 52-week low of $56.66, representing a potential loss of approximately -27% from the current price of $77.82. A breach of that level could lead to a further decline towards the stock's maximum drawdown level of -43.79% from its peak.
FAQ
The key risks are severe and multi-faceted. 1) Financial Risk: The company carries a dangerously high debt load, with a debt-to-equity ratio of 2.44, which creates solvency concerns if earnings falter. 2) Operational Risk: Profitability is deeply negative (trailing net margin of -7.93%) and highly volatile, as seen in swings from a -$546M to a +$162M net income quarter. 3) Market Risk: The stock is 25% more volatile than the market (beta of 1.252) and is in a pronounced downtrend, down 33.9% over three months. 4) Execution Risk: The success of the company's turnaround plan is uncertain, and failure could lead to further market share loss and credit downgrades. The financial and operational risks are currently the most severe.
The 12-month forecast is highly uncertain, centered around three scenarios. The Base Case (50% probability) sees a slow recovery with the stock trading between $80 and $100 as the company shows intermittent progress. The Bull Case (25% probability) involves a successful turnaround, with the stock re-rating towards the $105-$121 range (near its 52-week high) on sustained profit growth. The Bear Case (25% probability) envisions a failed turnaround, with the stock testing its 52-week low of $56.66, potentially falling into the $56-$70 range. The most likely outcome is the Base Case, predicated on the assumption that the company manages to stabilize but does not rapidly accelerate growth or significantly de-lever its balance sheet.
EL is deeply undervalued relative to its own historical trading range but may be fairly valued or even overvalued relative to its current broken fundamentals. The primary metric, the Price-to-Sales (PS) ratio, is 2.04, which is near the absolute bottom of its observable history (from ~6.70 to above 29). This suggests the market is pricing in extreme pessimism. However, with negative trailing earnings (EPS of -$0.04) and a negative net margin, traditional PE-based valuation is impossible. The market is effectively assigning a deep discount for the company's high financial risk and operational instability. The valuation implies the market expects either a prolonged recovery or further deterioration, with little premium for its brand strength.
EL is a high-risk, high-potential-reward stock that may be a good buy only for a specific type of investor. For risk-tolerant, deep-value investors willing to bet on a multi-year turnaround, the current price near a 52-week low and a historically low PS ratio of 2.04 could present an attractive entry point. The recent return to profitability in Q2 ($162M net income) and strong brand portfolio are positive signs. However, for most investors, the severe risks—including a high debt-to-equity ratio of 2.44, negative trailing ROE of -29.3%, and extreme stock price volatility (beta of 1.252)—make it a speculative hold rather than a clear buy. It is not suitable for conservative or income-focused portfolios.
EL is strictly a long-term, speculative investment and is unsuitable for short-term trading. The company's turnaround is a multi-year story, and the stock's high beta of 1.252 and recent downtrend make it far too volatile for short-term positioning. There is no meaningful dividend to support income investors (yield of 2.1%). Given the need for several quarters of consistent execution to repair profitability and balance sheet metrics, investors should be prepared for a holding period of at least 2-3 years to allow the thesis to play out. Short-term traders would be exposed to whipsaw price action driven by earnings volatility and sentiment shifts around the fragile recovery narrative.
